CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?

CAR-T, bispecifics and MRD: how is treatment for multiple myeloma evolving?

Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, gives his thoughts on how the treatment of multiple myeloma could evolve – including the continued use of CAR-Ts, the use of bispecific antibodies for maintenance therapy, and the importance of measurable residual disease (MRD) for patients. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Leave a Reply

Your email address will not be published.